{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:35:37Z","timestamp":1794944137318,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mesenchymal circulating tumor cells (M-CTCs) may be related to tumor progression, and Ki67 expression is known to be involved in tumor proliferation. The aim of the present study was to explore the relationship between M-CTCs and Ki67 in hepatocellular carcinoma (HCC) and their ability to predict prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Peripheral blood samples were obtained from 105 HCC patients before radical surgery. CTCs were isolated using CanPatrol enrichment and classified via in situ hybridization. Ki67 expression in HCC tissue was assessed through immunohistochemistry. Potential relationships of M-CTC, Ki67 with clinicopathological factors and prognosis were evaluated. Overall survival (OS) was analyzed using the Kaplan\u2013Meier method and Cox regression. The prognostic efficacy of M-CTC, Ki67 and both together (M-CTC\u2009+\u2009Ki67) was assessed in terms of time-dependent receiver operating characteristic (ROC) curves and Harrell's concordance index.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 105 patients, 50 were positive for M-CTCs (count\u2009\u2265\u20091 per 5\u00a0mL) and 39 showed high Ki67 expression (\u2265\u200950% tumor cells were Ki67-positive). The presence of M-CTC was significantly associated with alpha-fetoprotein (AFP)\u2009\u2265\u2009400\u00a0ng\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.007), tumor size\u2009\u2265\u20095\u00a0cm (<jats:italic>P<\/jats:italic>\u2009=\u20090.023), multiple tumors (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), poorly differentiated tumors (<jats:italic>P<\/jats:italic>\u2009=\u20090.003), incomplete tumor capsule (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), Barcelona Clinic liver cancer (BCLC) stage B or C (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), microvascular invasion (MVI) (<jats:italic>P<\/jats:italic>\u2009=\u20090.05) and portal vein tumor thrombosis (PVTT) (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). High Ki67 expression correlated with AFP\u2009\u2265\u2009400\u00a0ng\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.015), tumor size\u2009\u2265\u20095\u00a0cm (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), incomplete tumor capsule (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), MVI (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), PVTT (<jats:italic>P<\/jats:italic>\u2009=\u20090.003), advanced BCLC stage (<jats:italic>P<\/jats:italic>\u2009=\u20090.01), and vessel carcinoma embolus (VCE) (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). M-CTC positively correlated with Ki67. Patients positive for M-CTCs had a significantly shorter OS than patients negative for them. Similarly, high Ki67 expression was associated with a significantly lower OS. The high-risk group (positive for M-CTCs and high Ki67 expression) had worse OS than the other groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). Uni- and multivariate analyses showed that OS was independently predicted by M-CTC [hazard ratio (HR) 1.115; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001], Ki67 (HR 1.666; <jats:italic>P<\/jats:italic>\u2009=\u20090.046) and the combination of both (HR 2.885; <jats:italic>P<\/jats:italic>\u2009=\u20090.008). Based on ROC curves and the concordance index, the combination of M-CTC and Ki67 was superior to either parameter alone for predicting the OS of HCC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presence of M-CTC correlates with high Ki67 expression in HCC patients, and both factors are associated with poor prognosis. Furthermore, the combination of M-CTC and Ki67 is a useful prognostic indicator for predicting OS in patients with HCC after hepatectomy, performing better than either parameter on its own.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-10503-3","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:05:23Z","timestamp":1672877123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Xihua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanghang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwu","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangde","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"issue":"3","key":"10503_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10503_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10503_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","volume":"13","author":"T Couri","year":"2019","unstructured":"Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125\u201337.","journal-title":"Hepatol Int"},{"issue":"7","key":"10503_CR4","first-page":"101","volume":"111","author":"NP Malek","year":"2014","unstructured":"Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014;111(7):101\u20136.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"10503_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00432-004-0572-9","volume":"130","author":"LX Qin","year":"2004","unstructured":"Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130(9):497\u2013513.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"17","key":"10503_CR6","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/cancers13174334","volume":"13","author":"P Maravelia","year":"2021","unstructured":"Maravelia P, Silva DN, Rovesti G, Chrobok M, St\u00e5l P, Lu YC, et al. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers (Basel). 2021;13(17):4334.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10503_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398\u2013406.","journal-title":"Trends Mol Med"},{"issue":"3","key":"10503_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1309\/90BU6KDXANFLN4RJ","volume":"126","author":"GJ Tsongalis","year":"2006","unstructured":"Tsongalis GJ. Branched DNA technology in molecular diagnostics. Am J Clin Pathol. 2006;126(3):448\u201353.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10503_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798\u2013808.","journal-title":"J Hepatol"},{"issue":"3","key":"10503_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2013.03.004","volume":"23","author":"JP Thiery","year":"2013","unstructured":"Thiery JP, Lim CT. Tumor dissemination: an EMT affair. Cancer Cell. 2013;23(3):272\u20133.","journal-title":"Cancer Cell"},{"issue":"7","key":"10503_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/1878-0261.12081","volume":"11","author":"DS Micalizzi","year":"2017","unstructured":"Micalizzi DS, Haber DA, Maheswaran S. Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells. Mol Oncol. 2017;11(7):770\u201380.","journal-title":"Mol Oncol"},{"issue":"9","key":"10503_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12094-017-1652-z","volume":"19","author":"S Li","year":"2017","unstructured":"Li S, Chen Q, Li H, Wu Y, Feng J, Yan Y. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer. Clin Transl Oncol. 2017;19(9):1147\u201353.","journal-title":"Clin Transl Oncol"},{"issue":"47","key":"10503_CR13","doi-asserted-by":"publisher","first-page":"13259","DOI":"10.3748\/wjg.v21.i47.13259","volume":"21","author":"TT Li","year":"2015","unstructured":"Li TT, Liu H, Li FP, Hu YF, Mou TY, Lin T, et al. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. World J Gastroenterol. 2015;21(47):13259\u201367.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10503_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","volume":"39","author":"X Guan","year":"2019","unstructured":"Guan X, Ma F, Li C, Wu S, Hu S, Huang J, et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond). 2019;39(1):1\u20131.","journal-title":"Cancer Commun (Lond)."},{"issue":"1","key":"10503_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ijc.2910310104","volume":"31","author":"J Gerdes","year":"1983","unstructured":"Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13\u201320.","journal-title":"Int J Cancer"},{"key":"10503_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","volume":"491","author":"SS Menon","year":"2019","unstructured":"Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39\u201345.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10503_CR17","first-page":"2916","volume":"12","author":"H Peng","year":"2020","unstructured":"Peng H, Tan X, Wang Y, Dai L, Liang G, Guo J, et al. Clinical significance of Ki67 and circulating tumor cells with an epithelial-mesenchymal transition phenotype in non-small cell lung cancer. Am J Transl Res. 2020;12(6):2916\u201328.","journal-title":"Am J Transl Res"},{"issue":"1","key":"10503_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12957-021-02268-5","volume":"19","author":"J Song","year":"2021","unstructured":"Song J, Yu Z, Dong B, Zhu M, Guo X, Ma Y, et al. Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. World J Surg Oncol. 2021;19(1):156.","journal-title":"World J Surg Oncol"},{"key":"10503_CR19","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system (IARC WHO Classification of Tumours). 4th ed. International Agency for Research on Cancer. World Health Organization. 2010; p 5771\u20135418."},{"issue":"16","key":"10503_CR20","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-17-2459","volume":"78","author":"LN Qi","year":"2018","unstructured":"Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH, Wang YY, et al. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer Res. 2018;78(16):4731\u201344.","journal-title":"Cancer Res"},{"issue":"4","key":"10503_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s12072-016-9732-7","volume":"10","author":"YK Liu","year":"2016","unstructured":"Liu YK, Hu BS, Li ZL, He X, Li Y, Lu LG. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int. 2016;10(4):640\u20136.","journal-title":"Hepatol Int"},{"issue":"4","key":"10503_CR22","doi-asserted-by":"publisher","first-page":"e0123976","DOI":"10.1371\/journal.pone.0123976","volume":"10","author":"S Wu","year":"2015","unstructured":"Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS ONE. 2015;10(4):e0123976.","journal-title":"PLoS ONE"},{"issue":"3","key":"10503_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.21037\/tcr.2020.01.14","volume":"9","author":"T Bai","year":"2020","unstructured":"Bai T, Mai R, Ye J, Chen J, Qi L, Tang J, et al. Circulating tumor cells and CXCR4 in the prognosis of hepatocellular carcinoma. Translational Cancer Research. 2020;9(3):1384\u201394.","journal-title":"Translational Cancer Research"},{"issue":"1\u20132","key":"10503_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/07853890.2019.1709655","volume":"52","author":"LN Qi","year":"2020","unstructured":"Qi LN, Ma L, Chen YY, Chen ZS, Zhong JH, Gong WF, et al. Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. Ann Med. 2020;52(1\u20132):21\u201331.","journal-title":"Ann Med"},{"issue":"21","key":"10503_CR25","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10503_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.31165","volume":"73","author":"JC Ahn","year":"2021","unstructured":"Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422\u201336.","journal-title":"Hepatology"},{"issue":"9","key":"10503_CR27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s10620-018-5124-2","volume":"63","author":"H Ou","year":"2018","unstructured":"Ou H, Huang Y, Xiang L, Chen Z, Fang Y, Lin Y, et al. Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma. Dig Dis Sci. 2018;63(9):2373\u201380.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10503_CR28","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/cancers12123588","volume":"12","author":"T Okabe","year":"2020","unstructured":"Okabe T, Togo S, Fujimoto Y, Watanabe J, Sumiyoshi I, Orimo A, et al. Mesenchymal characteristics and predictive biomarkers on circulating tumor cells for therapeutic strategy. Cancers (Basel). 2020;12(12):3588.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10503_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","volume":"22","author":"N Tiwari","year":"2012","unstructured":"Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22(3):194\u2013207.","journal-title":"Semin Cancer Biol"},{"key":"10503_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2147\/OTT.S298576","volume":"14","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Xing W, Zhang J, Hu J, Qi L, Xiang B. Circulating tumor cells undergoing the epithelial-mesenchymal transition: influence on prognosis in cytokeratin 19-positive hepatocellular carcinoma. Onco Targets Ther. 2021;14:1543\u201352.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10503_CR31","doi-asserted-by":"publisher","first-page":"103969","DOI":"10.1016\/j.isci.2022.103969","volume":"25","author":"M Peralta","year":"2022","unstructured":"Peralta M, Osmani N, Goetz JG. Circulating tumor cells: Towards mechanical phenotyping of metastasis. iScience. 2022;25(3):103969.","journal-title":"iScience."},{"issue":"1","key":"10503_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41416-020-01176-x","volume":"124","author":"J Perea Paizal","year":"2021","unstructured":"Perea Paizal J, Au SH, Bakal C. Squeezing through the microcirculation: survival adaptations of circulating tumour cells to seed metastasis. Br J Cancer. 2021;124(1):58\u201365.","journal-title":"Br J Cancer"},{"issue":"12","key":"10503_CR33","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1007\/s11605-018-04067-y","volume":"23","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Luo L, Zhang J, Zhou M, Tang Y, He G, et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma. J Gastrointest Surg. 2019;23(12):2354\u201361.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10503_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11605-017-3619-3","volume":"22","author":"Z Wang","year":"2018","unstructured":"Wang Z, Luo L, Cheng Y, He G, Peng B, Gao Y, et al. Correlation between postoperative early recurrence of hepatocellular carcinoma and mesenchymal circulating tumor cells in peripheral blood. J Gastrointest Surg. 2018;22(4):633\u20139.","journal-title":"J Gastrointest Surg"},{"issue":"7","key":"10503_CR35","first-page":"10235","volume":"8","author":"Y Luo","year":"2015","unstructured":"Luo Y, Ren F, Liu Y, Shi Z, Tan Z, Xiong H, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med. 2015;8(7):10235\u201347.","journal-title":"Int J Clin Exp Med"},{"key":"10503_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1746-1596-6-121","volume":"6","author":"H Schmilovitz-Weiss","year":"2011","unstructured":"Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol. 2011;6:121.","journal-title":"Diagn Pathol"},{"issue":"3","key":"10503_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1440-1746.1998.01555.x","volume":"13","author":"KL King","year":"1998","unstructured":"King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13(3):273\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10503_CR38","first-page":"411","volume":"17","author":"C Stroescu","year":"2008","unstructured":"Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis. 2008;17(4):411\u20137.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"10503_CR39","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.7150\/thno.64252","volume":"12","author":"A Rodriguez-Martinez","year":"2022","unstructured":"Rodriguez-Martinez A, Simon-Saez I, Perales S, Garrido-Navas C, Russo A, de Miguel-Perez D, et al. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics. 2022;12(5):2150\u201361.","journal-title":"Theranostics"},{"key":"10503_CR40","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.2147\/OTT.S165244","volume":"11","author":"HH Li","year":"2018","unstructured":"Li HH, Qi LN, Ma L, Chen ZS, Xiang BD, Li LQ. Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. Onco Targets Ther. 2018;11:4747\u201354.","journal-title":"Onco Targets Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10503-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:06:13Z","timestamp":1672877173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10503-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10503"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10503-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Review Committee of the Affiliated Cancer Hospital of Guangxi Medical University (approval number: LW2022121). The requirement for informed consent to participate was waived by the Ethics Review Committee of the Affiliated Cancer Hospital of Guangxi Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}